Gyre Therapeutics, Inc. (NASDAQ:GYRE - Get Free Report) shares saw strong trading volume on Friday . 38,827 shares changed hands during mid-day trading, a decline of 47% from the previous session's volume of 73,103 shares.The stock last traded at $9.96 and had previously closed at $9.78.
Gyre Therapeutics Price Performance
The company has a 50-day moving average price of $13.07 and a 200-day moving average price of $12.57.
Institutional Inflows and Outflows
Institutional investors and hedge funds have recently added to or reduced their stakes in the company. FMR LLC purchased a new stake in shares of Gyre Therapeutics during the third quarter worth about $47,000. Barclays PLC grew its stake in Gyre Therapeutics by 281.8% in the 3rd quarter. Barclays PLC now owns 9,288 shares of the company's stock worth $116,000 after acquiring an additional 6,855 shares during the period. Rhumbline Advisers purchased a new stake in Gyre Therapeutics in the 2nd quarter worth approximately $123,000. Renaissance Technologies LLC acquired a new position in Gyre Therapeutics in the 2nd quarter valued at $166,000. Finally, Bank of New York Mellon Corp purchased a new position in shares of Gyre Therapeutics during the 2nd quarter worth $218,000. 23.99% of the stock is currently owned by hedge funds and other institutional investors.
Gyre Therapeutics Company Profile
(
Get Free Report)
Gyre Therapeutics, Inc, a biopharmaceutical company, primarily focuses on the development and commercialization of Hydronidone for the treatment of Metabolic Dysfunction Associated Steatohepatitis in the United States. Its Hydronidone is also being evaluated for the treatment of liver fibrosis across a spectrum of chronic liver diseases.
Further Reading
Before you consider Gyre Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Gyre Therapeutics wasn't on the list.
While Gyre Therapeutics currently has a "Hold" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Click the link below and we'll send you MarketBeat's list of the 10 best stocks to own in 2025 and why they should be in your portfolio.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
